# A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers

> **NCT05951946** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 37 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** BR3006-1
- **DRUG:** BR3006-2
- **DRUG:** BR3006-3

## Key facts

- **NCT ID:** NCT05951946
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-22
- **Primary completion:** 2023-09-11
- **Final completion:** 2023-09-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05951946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05951946, "A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05951946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*